Join senior operators from across biotech, treatment centres, and supply chain leadership for a discussion on where programs actually fail and what commercially ready organisations are doing differently.
From chain-of-identity and chain-of-custody pressures to fragmented digital infrastructure and governance gaps, this session will explore the operational realities emerging as advanced therapies move beyond the industry's first-wave operating models.
Co-hosted by Phacilitate and BlueSquared, the discussion brings together leaders working directly across CGT operations, manufacturing, treatment centre coordination, and digital enablement to unpack where friction is increasing and how organisations are adapting before those issues become commercial bottlenecks.
What you will leave with:
- A clearer understanding of where coordination failures actually happen across CGT programs
- Insight into why orchestration is becoming a distinct operational discipline in advanced therapies
- Practical perspectives from operators managing complexity across sites, modalities, and stakeholder groups
- A live view of how the audience scores across key operational maturity domains
- Access to BlueSquared's CGT Digital Orchestration Maturity Assessment, including a personalised 10-page report with maturity radar, gap analysis, and a 30-day action plan
Who should attend: This session is designed for senior professionals across:
- Cell and Gene Therapy Operations
- Patient Operations
- CGT Supply Chain and Logistics
- Digital and IT for Advanced Therapies
- CMC and Manufacturing Operations
- Quality and Governance
- Treatment Centre Operations
Webinar format:
- 60-minute online webinar
- Moderated practitioner panel
- Live audience polling and maturity diagnostic
- Interactive Q&A
- Co-hosted by Phacilitate and BlueSquared
Register now
Additional speakers:
- J. Andrew Case — Head of Supply Chain, Cell and Gene Therapies, Genentech/Roche
- Arthur Mallian — Senior Cell Therapy Operations, Bristol-Myers Squibb
- Ronit Slotky PhD, MSc, CABP — Director, Cell Therapies Manufacturing Facility, Hackensack University Medical Center